keyword
MENU ▼
Read by QxMD icon Read
search

rabeprazol

keyword
https://www.readbyqxmd.com/read/29154196/analysis-of-potential-genotoxic-impurities-in-rabeprazole-active-pharmaceutical-ingredient-via-liquid-chromatography-tandem-mass-spectrometry-following-quality-by-design-principles-for-method-development
#1
Katerina Iliou, Anđelija Malenović, Yannis L Loukas, Yannis Dotsikas
A novel Liquid Chromatography-tandem mass spectrometry (LC-MS/MS) method is presented for the quantitative determination of two potential genotoxic impurities (PGIs) in rabeprazole active pharmaceutical ingredient (API). In order to overcome the analytical challenges in the trace analysis of PGIs, a development procedure supported by Quality-by-Design (QbD) principles was evaluated. The efficient separation between rabeprazole and the two PGIs in the shortest analysis time was set as the defined analytical target profile (ATP) and to this purpose utilization of a switching valve allowed the flow to be sent to waste when rabeprazole was eluted...
November 12, 2017: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/29131124/comparison-of-helicobacter-pylori-eradication-rates-of-2-week-levofloxacin-containing-triple-therapy-levofloxacin-containing-bismuth-quadruple-therapy-and-standard-bismuth-quadruple-therapy-as-a-first-line-regimen
#2
Evrim Kahramanoğlu Aksoy, Ferdane Pirinçci Sapmaz, Zeynep Göktaş, Metin Uzman, Yaşar Nazlıgül
OBJECTIVE: The aim of this study was to compare the efficacy and safety of 2-week levofloxacin containing triple therapy, levofloxacin containing bismuth quadruple therapy and standard bismuth containing quadruple therapy as a first-line regimen for eradication of Helicobacter pylori (H pylori). METHODS: A total of 329 patients with H pylori infection were randomly divided into three groups to receive: a) levofloxacin containing bismuth quadruple therapy, RBAL (rabeprazole 20 mg b...
November 3, 2017: Medical Principles and Practice: International Journal of the Kuwait University, Health Science Centre
https://www.readbyqxmd.com/read/29022830/direct-costs-for-nonsurgical-management-of-chronic-pancreatitis-in-a-tertiary-care-teaching-hospital
#3
Nagesh Kamat, Ganesh Pai, Surulivel Rajan Mallayasamy, Asha Kamath, Rajasulochana S
BACKGROUND: Chronic pancreatitis (CP) is a leading cause of hospitalization among gastrointestinal diseases resulting in considerable financial burden to patients. However the direct costs for nonsurgical management in CP remains unexplored. METHODS: A cross sectional study was carried out (2011-14) in the Department of Gastroenterology, Kasturba Hospital, Manipal, India. Demographic and clinical data on laboratory investigations, interventions and follow up were obtained from the medical records department...
October 12, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28964908/interchageable-use-of-proton-pump-inhibitors-based-on-relative-potency
#4
David Y Graham, Aylin Tansel
Although proton pump inhibitors (PPIs) are widely used, their relative potency and ideal dosing regimens remain unclear. We analyzed data from randomized clinical trials that performed pH testing in patients receiving solid-dose PPI formulations (omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole) for a minimum of 5 days. We used omeprazole equivalency and the surrogate biomarker, pH4time (percentage time pH>4 over 24-hour period), to compare PPI effectiveness for different PPIs given once, twice or three times daily...
September 28, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28953640/comparative-effectiveness-and-acceptability-of-the-fda-licensed-proton-pump-inhibitors-for-erosive-esophagitis-a-prisma-compliant-network-meta-analysis
#5
Mei-Juan Li, Qing Li, Min Sun, Li-Qin Liu
BACKGROUND: This study compared the effectiveness and acceptability of all Food and Drug Administration (FDA)-recommended dose proton pump inhibitors (PPIs) in erosive esophagitis (EE): Dexlansoprazole 60 mg, Esomeprazole 40 mg, Esomeprazole 20 mg, Pantoprazole 40 mg, Lansoprazole 30 mg, Rabeprazole 20 mg, Omeprazole 20 mg. METHODS: A systematic literature search was performed using PubMed, Embase, and Cochrane Library. Totally, 25 randomized controlled trials (RCTs) met study selection criteria and were incorporated in this network meta-analysis (NMA) study...
September 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28937021/optimized-high-dose-amoxicillin-proton-pump-inhibitor-dual-therapies-fail-to-achieve-high-cure-rates-in-china
#6
Jia-Li Hu, Jun Yang, Yin-Bin Zhou, Ping Li, Ran Han, Dian-Chun Fang
Background\Aim: Quadruple daily administration of proton-pump inhibitor (PPI) therapy achieves potent acid inhibition, and combined with amoxicillin, with its pharmacodynamic and pharmacokinetic characteristics, may be efficient for Helicobacter pylori eradication. We compared the efficacy of two optimized high-dose dual therapies with a bismuth-containing quadruple regimen for treating H. pylori infection. Rabeprazole dosages for H. pylori eradication were also evaluated. PATIENTS AND METHODS: Treatment-naive and H...
September 2017: Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association
https://www.readbyqxmd.com/read/28912807/a-meta-analysis-and-systematic-review-of-the-efficacy-of-twice-daily-ppis-versus-once-daily-for-treatment-of-gastroesophageal-reflux-disease
#7
REVIEW
Hongying Zhang, Zhiping Yang, Zhen Ni, Yongquan Shi
BACKGROUND: To investigate whether PPIs BID is superior to QD for treatment of GERD in a short time. METHODS: We searched PubMed, Cochrane Library, Scopus, EMBASE, Ovid, EBSCO, and Web of Science databases (from 1998 to May 2016) to select RCTs, which compared the efficacy of PPIs BID versus QD for GERD. The primary outcomes were symptom relief or esophageal mucosal healing at weeks 4 and 8. The M-H method with fixed-effect or random-effect model was used to calculate RR and 95% CIs...
2017: Gastroenterology Research and Practice
https://www.readbyqxmd.com/read/28889052/a-rapid-fourier-transform-infrared-spectroscopic-method-for-analysis-of-certain-proton-pump-inhibitors-in-binary-and-ternary-mixtures
#8
Pakinaz Y Khashaba, Hassan Refat H Ali, Mohamed M El-Wekil
A simple and non-destructive FTIR method was used to determine certain proton pump inhibitors (PPIs) in binary and ternary mixtures. Proton pump inhibitors (PPIs); omeprazole (OMZ), esomeprazole (EZM), lansoprazole (LAN), pantoprazole sodium (PAN sodium) and rabeprazole sodium (RAB sodium) in binary mixture with domperidone (DOM) and ternary mixture of OMZ, clarithromycin (CLM) and tinidazole (TNZ) were determined in the solid-state by FTIR spectroscopy for the first time. The method was validated according to ICH-guidelines where linearity was ranged from 20 to 850μg/g and 20-360μg/g for PPIs and DOM, respectively in binary mixtures and 10-400, 100-8000 and 150-14,000μg/g for OMZ, CLM and TNZ, respectively...
September 5, 2017: Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy
https://www.readbyqxmd.com/read/28865098/therapy-of-gerd-and-fd-overlap-with-symptoms-after-usual-dose-ppi-acotiamide-plus-usual-dose-ppi-vs-double-dose-ppi
#9
Toshihisa Takeuchi, Yoshiaki Takahashi, Shinpei Kawaguchi, Kazuhiro Ota, Satoshi Harada, Yuichi Kojima, Hiroki Sakamoto, Takanori Kuramoto, Keishi Kojima, Makoto Sanomura, Masahiro Hoshimoto, Takeshi Higashino, Tsukasa Itabashi, Ko Takada, Masahiro Sakaguchi, Kazunari Tominaga, Motoyasu Kusano, Kazuhide Higuchi
BACKGROUND AND AIM: Gastroesophageal reflux disease (GERD) and functional dyspepsia (FD) often coexist or overlap. In this study, the efficacy of acotiamide in combination with a standard dose of rabeprazole for GERD and FD was compared with that of a double dose of rabeprazole. METHODS: Patients with overlap between GERD and FD experiencing heartburn and epigastric fullness symptoms after standard-dose proton pump inhibitor (PPI) for ≥8 weeks were randomized into two groups, and received either acotiamide 300 mg/day + rabeprazole 10 mg/day or rabeprazole 20 mg/day for 4 weeks...
September 1, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28859358/a-review-of-medical-therapy-for-proton-pump-inhibitor-nonresponsive-gastroesophageal-reflux-disease
#10
L Hillman, R Yadlapati, A J Thuluvath, M A Berendsen, J E Pandolfino
Up to 40% of patients report persistent gastroesophageal reflux disease (GERD) symptoms despite proton pump inhibitor (PPI) therapy. This review outlines the evidence for medical therapy for PPI nonresponsive GERD. A literature search for GERD therapies from 2005 to 2015 in PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews identified 2928 unique citations. Of those, 40 unique articles specific to the impact of PPI metabolizer genotype on PPI response and the use adjunctive medical therapies were identified...
September 1, 2017: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
https://www.readbyqxmd.com/read/28845910/successful-eradication-of-helicobacter-pylori-with-a-herbal-medicine-goshuyuto-wu-zhu-yu-tang-plus-rabeprazole-after-failure-of-triplet-therapy-with-vonoprazan-a-report-of-three-cases
#11
Yutaka Nagata, Kazuhiko Nagasaka, Syunpei Koyama, Mai Murase, Minoru Saito, Toshinori Yazaki, Nobutoshi Komatsu, Takayuki Murase, Toshiki Uehara, Norihide Taniuchi
Vonoprazan, a potassium-competitive acid blocker, is used as a substitute drug for conventional proton pump inhibitors. Recently, vonoprazan has been applied for eradication of H. pylori (HP) infection, and the efficacies of vonoprazan-based triple therapy against HP infection have already been reported. However, treatment sometimes fails in the primary and/or secondary triplet eradication therapy, including with the use of vonoprazan for HP infection. We experienced three cases of refractory HP infection. They were treated with eradication therapy for HP infection with chronic gastritis...
August 28, 2017: Journal of Digestive Diseases
https://www.readbyqxmd.com/read/28830132/-the-efficacy-of-moxifloxacin-containing-triple-therapy-after-hybrid-therapy-failure-in-helicobacter-pylori-eradication
#12
Soohoon Kwon, Dong Ho Lee, Jae Bin Kang, Nayoung Kim, Young Soo Park, Cheol Min Shin, Hyuk Yoon, Yoon Jin Choi
Background/Aims: Hybrid therapy was successful in eradicating Helicobacter pylori (H. pylori) according to previous reports. However, to the best of our knowledge, there have only been a few studies evaluating the optimal choice after hybrid failure. Hence, we aimed to evaluate the efficacy of moxifloxacin-containing triple therapy after hybrid therapy failure in H. pylori eradication. Methods: Between January 2013 and March 2016, we retrospectively reviewed patients who underwent failed hybrid therapy, as first line treatment, in eradicating H...
August 25, 2017: Korean Journal of Gastroenterology, Taehan Sohwagi Hakhoe Chi
https://www.readbyqxmd.com/read/28822453/-influence-of-saccharomyces-boulardii-sachets-combined-with-bismuth-quadruple-therapy-for-initial-helicobacter-pylori-eradication
#13
X Y Zhu, J Du, J Wu, L W Zhao, X Meng, G F Liu
Objective: To evaluate the efficacy and safety of Saccharomyces boulardii Sachets combined with bismuth quadruple therapy for initial Helicobacter pylori(H.pylori) eradication. Methods: From March 2014 to March 2015, 240 participants from the third hospital of Hebei medical university with H. pylori infection were recruited and randomized into three groups: Quadruple therapy group received bismuth potassium citrate 220 mg bid + Rabeprazole 10 mg bid + amoxicillin 1 000 mg bid+ furazolidone 100 mg bid for 10 days...
August 8, 2017: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/28801980/effects-of-proton-pump-inhibitors-and-famotidine-on-elimination-of-plasma-methotrexate-evaluation-of-drug-drug-interactions-mediated-by-organic-anion-transporter-3
#14
Katsuya Narumi, Yu Sato, Masaki Kobayashi, Ayako Furugen, Kumiko Kasashi, Takehiro Yamada, Takanori Teshima, Ken Iseki
Methotrexate (MTX) is an antifolate agent used in the treatment of numerous types of cancer, and eliminated by active tubular secretion via organic anion transporter 3 (OAT3). Gastric antisecretory drugs, such as proton pump inhibitors (PPIs) and histamine H2 receptor antagonists, are widely used among patients with cancer in clinical practice. The aim of the present study was to analyze the potential drug-drug interactions between MTX and gastric antisecretory drugs in high-dose MTX (HD-MTX) therapy. We retrospectively analyzed the impact of PPIs on the plasma MTX concentration on 73 cycles of HD-MTX therapy performed in 43 patients...
August 12, 2017: Biopharmaceutics & Drug Disposition
https://www.readbyqxmd.com/read/28791044/adding-bismuth-to-rabeprazole-based-first-line-triple-therapy-does-not-improve-the-eradication-of-helicobacter-pylori
#15
Meng-Chieh Wu, Yao-Kuang Wang, Chung-Jung Liu, Fang-Jung Yu, Fu-Chen Kuo, Min-Li Liu, Chao-Hung Kuo, Deng-Chyang Wu, Yao-Kang Huang, I-Chen Wu
This randomized controlled study aimed to evaluate whether adding bismuth to the standard first-line triple therapy could improve the eradication rate of Helicobacter pylori. A total of 162 patients with Helicobacter pylori infection were randomly assigned to either the 7-day triple therapy group (RAK regimen: rabeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg bid; n = 81) or the bismuth plus triple therapy group (n = 81). In the RBAK group, bismuth subcitrate 360 mg twice daily was added to the RAK regimen...
2017: Gastroenterology Research and Practice
https://www.readbyqxmd.com/read/28688035/metformin-accelerates-glycolytic-lactate-production-in-cultured-primary-cerebellar-granule-neurons
#16
Eva-Maria Blumrich, Ralf Dringen
Metformin is the most frequently used drug for the treatment of type-II diabetes. As metformin has been reported to cross the blood-brain barrier, brain cells will encounter this drug. To test whether metformin may affect the metabolism of neurons, we exposed cultured rat cerebellar granule neurons to metformin. Treatment with metformin caused a time- and concentration-dependent increase in glycolytic lactate release from viable neurons as demonstrated by the three-to fivefold increase in extracellular lactate concentration determined after exposure to metformin...
July 7, 2017: Neurochemical Research
https://www.readbyqxmd.com/read/28674348/randomized-trial-comparing-esomeprazole-and-rabeprazole-in-first-line-eradication-therapy-for-helicobacter-pylori-infection-based-on-the-serum-levels-of-pepsinogens
#17
Tadashi Shimoyama, Daisuke Chinda, Yoshihiko Sawada, Kazuo Komai, Hironobu Chiba, Yoshiharu Saito, Yoshio Sasaki, Masashi Matsuzaka, Shinsaku Fukuda
Objective CYP2C19 metabolic activity influences the efficacy of Helicobacter pylori eradication therapies comprising PPIs. Rabeprazole (RPZ) and esomeprazole (EPZ) are PPIs not extensively metabolized by CYP2C19. The aim of this study was to elucidate whether or not first-line triple therapies using RPZ or EPZ are equally effective in Japanese patients with different CYP2C19 genotypes. Methods Two-hundred patients infected with H. pylori were randomized to receive one of the following regimens: amoxicillin (750 mg), clarithromycin (200 mg), and either esomeprazole (20 mg) (EAC group) or rabeprazole (10 mg) (RAC group), twice a day for one week...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28655978/early-effect-on-intragastric-ph-of-oral-administration-of-rabeprazole-with-mosapride-compared-with-rabeprazole-alone
#18
Hiroshi Iida, Megumi Kaai, Yumi Inoh, Kenji Kanoshima, Kanji Ohkuma, Takashi Nonaka, Koji Fujita, Tomonori Ida, Akihiko Kusakabe, Shin Maeda, Atsushi Nakajima, Masahiko Inamori
BACKGROUND: An ideal medication for acid-related diseases would offer prompt stopping of blood flow as well as efficient symptom resolution. The aim of this study was to investigate the gastric acid suppression potency of a single oral dose of rabeprazole alone, compared with administration of rabeprazole plus mosapride. METHODS: Twelve male volunteers, Helicobacter pylori (H. pylori)-negative, participated in this randomized, three-way crossover study. After a single oral administration of rabeprazole, rabeprazole with mosapride, or rabeprazole administered 1 h after mosapride, we monitored their intragastric pH constantly for 6 h...
2017: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/28644575/comparison-of-10-day-levofloxacin-bismuth-based-quadruple-therapy-and-levofloxacin-based-triple-therapy-for-helicobacter-pylori
#19
Tzung-Shiun Wu, Ping-I Hsu, Chao-Hung Kuo, Huang-Ming Hu, I-Chen Wu, Sophie S W Wang, Yen-Hsu Chen, Deng-Chyang Wu, Wei-Wen Su, Fu-Chen Kuo
OBJECTIVE: This was a prospective study aiming to investigate whether levofloxacin plus bismuth-based quadruple therapy was more effective than levofloxacin-based triple therapy after failed first-line eradication therapies for Helicobacter pylori (H. pylori) infection. METHODS: Sixty-seven patients infected with H. pylori were randomly assigned to two groups; the levofloxacin plus bismuth-based quadruple therapy group (RBAL [n = 33]; rabeprazole 20 mg twice daily, bismuth subcitrate 120 mg four times daily, amoxicillin 1 g twice daily and levofloxacin 500 mg once daily, for 10 days) and the levofloxacin-based triple therapy group (RAL [n = 34]; rabeprazole 20 mg twice daily, amoxicillin 1 g twice daily and levofloxacin 500 mg once daily, for 10 days)...
September 2017: Journal of Digestive Diseases
https://www.readbyqxmd.com/read/28588208/human-dimethylarginine-dimethylaminohydrolase-1-inhibition-by-proton-pump-inhibitors-and-the-cardiovascular-risk-marker-asymmetric-dimethylarginine-in-vitro-and-in-vivo-significance
#20
S Tommasi, D J Elliot, J A Hulin, B C Lewis, M McEvoy, A A Mangoni
Proton pump inhibitor (PPI)-induced inhibition of dimethylarginine dimethylaminohydrolase 1 (DDAH1), with consequent accumulation of the nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA), might explain the increased cardiovascular risk with PPI use. However, uncertainty exists regarding whether clinical PPI concentrations significantly inhibit DDAH1 under linear initial rate conditions, and whether PPI-induced DDAH1 inhibition significantly increases ADMA in humans. DDAH1 inhibition by esomeprazole, omeprazole, pantoprazole, lansoprazole and rabeprazole was determined by quantifying DDAH1-mediated L-citrulline formation in vitro...
June 6, 2017: Scientific Reports
keyword
keyword
93726
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"